About Elucida Oncology
Elucida Oncology is a company based in Santa Barbara (United States) founded in 2014.. Elucida Oncology has raised $81.54 million across 4 funding rounds. Elucida Oncology operates in a competitive market with competitors including Abingdon Health, Sirnaomics, Acorda, Liquidia and Genedit, among others.
- Headquarter Santa Barbara, United States
-
Sectors
TechnologyHealthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$81.54 M (USD)
in 4 rounds
-
Latest Funding Round
$44 M (USD), Series B
Jan 12, 2021
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Elucida Oncology
Elucida Oncology has successfully raised a total of $81.54M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $44 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $44.0M
- First Round First Round
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Series B - Elucida Oncology | Valuation |
investors |
|
| Jun, 2020 | Amount | Series A - Elucida Oncology | Valuation |
investors |
|
| Feb, 2019 | Amount | Series A - Elucida Oncology | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Elucida Oncology
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Elucida Oncology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Elucida Oncology Comparisons
Competitors of Elucida Oncology
Elucida Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abingdon Health, Sirnaomics, Acorda, Liquidia and Genedit, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of immunoassays for diagnostic purposes
|
|
| domain | founded_year | HQ Location |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| domain | founded_year | HQ Location |
Engaged in the development and commercialization of therapies that improve neurological function.
|
|
| domain | founded_year | HQ Location |
Engineered particles & films for life and material sciences applications
|
|
| domain | founded_year | HQ Location |
Genetic medicines are delivered using polymer nanoparticle platforms.
|
|
| domain | founded_year | HQ Location |
Drug delivery systems to cell interiors are developed via nanosyringes.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Elucida Oncology
Frequently Asked Questions about Elucida Oncology
When was Elucida Oncology founded?
Elucida Oncology was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Where is Elucida Oncology located?
Elucida Oncology is headquartered in Santa Barbara, United States. It is registered at Santa Barbara, California, United States.
Is Elucida Oncology a funded company?
Elucida Oncology is a funded company, having raised a total of $81.54M across 4 funding rounds to date. The company's 1st funding round was a Series A of $28.76M, raised on Apr 03, 2017.
What does Elucida Oncology do?
Elucida Oncology is a developer of a particle delivery platform using nanotechnology. The platform is called ultra-small C dot technology, it encapsulates near-infrared dye with a rigid silica shell which is coated with a layer of polyethylene glycol (PEG). PEG also acts as an ideal linker for a broad variety of ligands. The company claims a 95 clearance of C-dots through the renal system. The company has developed an Image-Guided Sentinel Lymph Node Mapping product, Nanoparticle Drug Conjugates, Nanoparticle Radiotherapeutic Conjugates, Multiplexing: Tumor Nerve Tissue, PET imaging, and others.
Who are the top competitors of Elucida Oncology?
Elucida Oncology's top competitors include Sirnaomics, Arcturus Therapeutics and Acorda.